Thalidomide in elderly patients with multiple myeloma

Lancet

Volumn 367, Issue 9527, 2006, Pages 1977-

  Kusumi, Eiji ^a   Matsumura, Tomoko ^a   Yuji, Koichiro ^a   Tanaka, Yuji ^a   Kami, Masahiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; MELPHALAN; PREDNISONE; THALIDOMIDE; IMMUNOSUPPRESSIVE AGENT;

AGED; CLINICAL FEATURE; DOSE RESPONSE; DRUG SAFETY; HUMAN; LETTER; MULTIPLE MYELOMA; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DRUG COMBINATION; MORTALITY; NOTE;

AGED; AGED, 80 AND OVER; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 33744997203     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68876-4     Document Type: Letter

References (4)

1. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
2. Barlogie B., Tricot G., Anaissie E., et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354 (2006) 1021-1030
3. Rajkumar S., Blood E., Vesole D., Fonseca R., and Greipp P. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
4. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571